REG - BioPharma Credit PLC - Notice of Full Year Results

Biopharma CreditAnnouncement

03/02/2026 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260203:nRSC4029Ra&default-theme=true

RNS Number : 4029R  BioPharma Credit PLC  03 February 2026

BioPharma Credit PLC

 

3 February 2026

BIOPHARMA CREDIT PLC

(the "Company")

NOTICE OF FULL YEAR RESULTS

 

BioPharma Credit PLC (LSE: BPCR), the specialist life sciences debt investor,
will announce its audited Full Year Results for the period ending 31 December
2025 on Tuesday 24 March 2026.

A management presentation will be delivered at 14.00 GMT through a webcast
facility. To register to attend or request details, RSVP
to biopharmacredit@buchanan.uk.com (mailto:biopharmacredit@buchanan.uk.com) .

-Ends-

Enquiries:

BioPharma Credit plc

via MUFG Corporate Governance Limited

Company Secretary

+44 (0) 333 300 1932

Burson Buchanan

Mark Court / Jamie Hooper / Henry Wilson / Nick Croysdill

+44 (0) 20 7466 5000

biopharmacredit@buchanan.uk.com (mailto:biopharmacredit@buchanan.uk.com)

 

Notes to Editors:

BioPharma Credit PLC is London's only listed specialist investor in debt
from the life sciences industry and joined the LSE on 27 March 2017. The
Company seeks to provide long-term shareholder returns, principally in the
form of sustainable income distributions from exposure to the life sciences
industry. The Company seeks to achieve this objective primarily through
investments in debt assets secured by royalties or other cash flows derived
from the sales of approved life sciences products.

LEI: 213800AV55PYXAS7SY24

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NORGZGGZRZFGVZM



            Copyright 2019 Regulatory News Service, all rights reserved